BioAtla Inc (NAS:BCAB)
$ 2.05 0.3 (17.14%) Market Cap: 98.64 Mil Enterprise Value: 5.50 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 35/100

Bioatla Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 03:30PM GMT
Release Date Price: $3.71 (+1.37%)
Jay Short
BioAtla, Inc. - Chairman, CEO, & Cofounder

Well, thank you, everyone, for coming. I think we look forward to sharing with you a bit today about BioAtla. And I just want to start off before we get into any of the questions and so forth and just mention that the company is headquartered in San Diego, California. It was founded in 2007.

And what's really unique about the company is its CAB technology, conditionally active biologics. These are antibody-based therapeutics that are reversible and only have an ability to bind to target if it's on a cancer cell. If that same target happens to be on a normal cell, they won't touch it. And this is very different than the past where you often will have to take a cancer therapeutic, and it's a race between whether it kills the cancer or does harm to the individual on its normal -- on their normal cells.

So having a technology that's very specific and targeted to a cancer cell is not dependent on what is already existing on that cell is fundamental. And it's a technology that was pioneered at BioAtla, and we have over 700 patents,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot